Introducing Liver Surgery to the MID NORTH COAST NSW Dr George Petrou FRACS 69Lake Rd, Port Macquarie NSW www.portlapsurgery.com.au Hepatobiliary Surgery,

Slides:



Advertisements
Similar presentations
Is there a role for surgery in metastatic colorectal cancer?
Advertisements

Pre-operative Imatinib for metastatic, recurrent and locally advanced GISTs E. Efthimiou, S Mudan E. Efthimiou, S Mudan On behalf of the Sarcoma Group.
Thoracic Surgery Innovations
Implementing NICE guidance
Diagnosis.
PET/CT in Oncology George Segall, M.D. Stanford University.
IN THE NAME OF GOD. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy The American Journal.
Mario Scartozzi Clinica di Oncologia Medica Ancona HIGHLIGHTS IN COLORECTAL CANCER MANAGEMENT TREATMENT OF METASTATIC DISEASE.
Dr. Carles Pericay Pijaume
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Merseyside and Cheshire Cancer Network HEPATO BILIARY MULTIDISCIPLINIARY TEAM MEETING Referral to Specialist HPB (Liver) MDT, University Hospital, Aintree,
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
1 Surgical and Ablative Strategies for Treatment of Metastatic Colorectal Cancer Kim M. Olthoff, MD Associate Professor of Surgery Liver Transplantation.
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
JHSGR 16 th April 2011 Dr Lee Man Kit Derek.  The value of PET in staging adenocarcinoma (e.g. colorectal cancer) is well established Tomoharu T. et.
Ayman Abdo MD, AmBIM, FRCPC
Management of Colorectal Liver Metastasis
Application of Positron Emission Tomography ( PET ) in Colorectal Cancer Dr Chan Wai Keung Department of Surgery Ruttonjee and Tang Shiu Kin Hospitals.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Colorectal cancer Khayal AlKhayal MD,FRCSC
Results of minor and major hepatectomies by laparoscopy Brice Gayet, Vibert E, Kouider A Department of digestive pathology Montsouris Institute, Paris,
Cancer Card Game Answers etc.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Biliary Tumors Cholangiocarcinoma and Cancer of the Gall Bladder
Joint Hospital Grand Round 20 th May 2006 Catherine Choi United Christian Hospital.
Consultant Radiologist Prince Sultan Military Medical City
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
Guzman, Alexander Joseph Hipolito, April Lorraine
The 53 rd International Congress of the Egyptian Society of Chest diseases and tuberculosis March 2012 Cairo.
Colorectal cancer Khayal AlKhayal MD,FRCSC Assistant professor of Surgery Consultant Colorectal surgeon 9/11/2015Shwartz.
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Resection For Lung Metastases M62 Coloproctology Course.
ACRIN 6673 Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients: A Multi-Center Study.
Common small and large intestinal surgical diseases Part II
PANCREATIC CANCER.
T4 Colon Cancer and Laparoscopic Approach Gustavo Plasencia MD FACS, FASCRS Clinical Professor of Surgery Gustavo Plasencia MD FACS, FASCRS Clinical Professor.
© 2008 Luzerner Kantonsspital Advanced Pancreatic Cancer Swiss Tumorboard, Berne PD Dr. J. Metzger Chefarzt.
PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.
Therapeutic Significance of D-dimer Cut-off Level of more than 3 µg/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Junji Furusez Junji Furusez Professor Department of Internal Medicine Kyorin University Japan.
SWISS TUMOR BOARD Lung Cancer March 26, 2009 Novotel Bern Prof. Dr. Mahmut Ozsahin Lausanne University Medical Center (CHUV), Lausanne.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.
LCC REC-1 Φ π π π Φ Φ See Primary and Adjuvant Treatment (LCC REC-3) Observe or See Primary Treatment (LCC REC-3) Rectal Cancer.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Evidence Based Approach 5-Year Survival Rate for Breast Cancer Stage IV is 14% 2 to 5 percent become long-term survivors, possibly cured of their disease.
EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.
Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Consultant Obstetrician & Gynaecologist
Malignant hepatic lesions Prepared by: Dr. yasser Baashan.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance
Melanoma Staging an update
Cancer Hospital & Institute, Chinese Academy of Medical Sciences
COLORECTAL LIVER METASTASES:
2epart EXTRAPULMONARY SMALL CELL CANCER OF THE ESOPHAGUS INTRODUCTION
Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers.
Functional imaging in liver tumours
ASSESSMENT & SURGERY OF LIVER METASTASES
Neoadjuvant Adjuvant Curative Palliative
James D Luketich, Michael E Burt  The Annals of Thoracic Surgery 
Presentation transcript:

Introducing Liver Surgery to the MID NORTH COAST NSW Dr George Petrou FRACS 69Lake Rd, Port Macquarie NSW Hepatobiliary Surgery, Laparoscopic Surgery, Obesity Surgery, Hernia surgery, Endosurgery

Indications for liver surgery Colorectal metastases Hepatocellular carcinoma Cholangiocarcinoma Neuroendocrine tumours Hepatic sarcomas Some benign lesions Select metastases- breast, gastric, pancreatic, melanoma

Colorectal Cancer 2 nd most common cancer in Australia 2 nd cancer killer 50% patients with colorectal cancer have or will develop liver metastases 15% patients have liver metastases at time of diagnoses of primary 120 colorectal cancer resections performed in Port Macquarie per year

Selecting patients for liver surgery Fit for major abdominal surgery. 30% normal functioning liver remnant. Size and number of tumours in the liver does not determine operability. Site of the tumour is more relevant. Patients eligible for surgery – 40-50%

Patient work up to determine operability Routine blood tests. Triple phase CT abdomen and CT chest. Liver directed MRI. CT PET used in selective cases (suspected extrahepatic disease or recurrent colorectal cancer). Multidisciplinary team discussion. Anaesthetic work up.

New Chemotherapy FOLFOX- median survival 24 months New agents are pushing this 2 year hurdle successfully FOLFIRI, FOLFOXFIRI +/- VEG inhibitors Now chemo alone med survival > 2 years 5 year hurdle is only a matter of time

Neoadjuvant Chemotherapy Preoperative chemotherapy before liver surgery. Improves survival & increases operability.

Inoperable

After Neoadjuvant chemotherapy this is now operable

RESECTION

Margins A clear margin is necessary to prevent local recurrence in the liver

Survival: marginal status Transection with CUSA (destroys 1cm) Inspect margin macroscopically R0 microscopically clear (>1mm) R1microscopically involved (<1mm) R2macroscopically involved (edge ablation)

Survival: marginal status

Extrahepatic Disease Rule: excise when minimal

Pre-operative PET scan

Survival: Extrahepatic Disease

Synchronous Resection with bowel Rule: safe if minor liver resection is planned (2 or less liver segments to be removed)

Survival: Synchronous vs Metachronous

Number of lesions Rule: Doesn’t matter provided a clear margin and adequate remnant liver volume can be achieved.

Survival: No. of lesions

Portal Vein Embolisation Increases operability and safety with extended resection.

Small L Lateral Inoperable as not enough remnant liver left to make surgery safe

Right portal vein is radiologically embolised as a day procedure

The remnant liver grows after 4-6 weeks

RESECTION The tumour is now operable as surgery is now safe

Is it safe?

Literature Morbidity Morbidity 20-30% Bleeding 1-3% Bile leaks 10-30% Infection 10-30% Liver failure < 5% Wound problems 20% PE DVT 1-3%

Morbidity and Mortality Australia 30 day mortality 1-5% (3%) AUSTRALIA Only 3 centres have reported data 90% St George Hospital 10% Adelaide and Melbourne ANZHPBA consensus- centre should be doing 10 major resections per year

Local Expertise

Mid North Coast NSW Established GIT MDT (Cancer Care Centre) Easily accessible high definition CT and MRI PET- important for recurrent colon cancer Established interventional radiology with experience in percutaneous drain placement Theatre team with experience in major vascular and GIT surgery Anaesthetic and ICU experience in major vascular and GIT surgery Established GIT medical oncology

5 year results Port Macquarie NSW Surgeon- George Petrou FRACS

Feb 2008-Jan 2013 Total- 55 liver resections Benign 12 (21.8%) Malignant 43 (78.2%) 22 (40%) Major liver resection completed (more than 2 segments removed) 33 (60%) Minor liver resections completed (2 or less liver segments removed) Major liver resection and bile duct resection 2 Combined liver resection with bowel resection 4 Redo liver resection for colorectal cancer recurrence 3 Colorectal cancer metastases 27 Cholangiocarcinoma 4 HCC 4 Gallbladder cancer 1 SI cancer 1 Neuroendocrine tumour 1 30 day mortality 2 (3.6%)

morbidity Suppurative infection 5 (9.1%) Wound dehiscence 2(3.6%) Incomplete tumour excision (0%) Pulmonary infection 2(3.6%) Pulmonary embolus 2(3.6%) Bile leak 4(7.3%) Anastomotic leak 1(1.8%) Liver failure 1(1.8%) Overwhelming sepsis 1(1.8%) Reoperation 2(3.6%)

Laparoscopic US George Petrou FRACS The liver tumour is easily seen at operation with US

Summary Introducing Liver Surgery to a Regional Hospital Challenging but exciting time Enthusiastic and supportive colleagues Preliminary results encouraging Volume increasing Prometheus stole the secret of fire and gave it to man